Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.

ABSTRACT:

Background

Single-agent immunotherapy is currently the recommended second-line therapy for patients with advanced non-small cell lung cancer (NSCLC) without targetable mutations; however, the objective response rate (ORR) remains low. This phase II study evaluated the efficacy of the combination therapy of sintilimab plus docetaxel and explored potential biomarkers for efficacy prediction.

Methods

Thirty patients with NSCLC without targetable mutations whose disease progressed from first-line platinum-based chemotherapy from October 2019 to December 2020 were enrolled in this single-arm, single-center, phase II trial. Sintilimab (200 mg) and docetaxel (75 mg/m²) were administered every 3 weeks until progression. The primary endpoint was ORR. Secondary endpoints in

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC9446552 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature